| Name | Title | Contact Details |
|---|
Transcept Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
STEMCELL Technologies is a biotechnology company that develops specialty cell culture media and cell separation products to support research in the fields of immunology, hematology, neuroscience, mesenchymal cell, stem cell and epithelial cell biology. We also provide instruments, cytokines, antibodies, training courses, proficiency testing and contract assay services. Driven by science and a passion for quality, STEMCELL delivers over 2500 products to more than 80 countries worldwide. STEMCELL Technologies provides consistent, unfailing quality and one-on-one assistance to help you succeed. We do this because we love science as much as you do.
Noxilizer, Inc. provides room-temperature nitrogen dioxide sterilization technology that offers many benefits over traditional sterilization methods. Noxilizer sells sterilization equipment to pharmaceutical, biotech and medical device manufacturers and also offers contract sterilization services at its Baltimore, MD facilities. Noxilizer’s expert microbiology and material compatibility team is ready to partner to solve sterilization challenges through every phase of the process. Noxilizer, Inc., founded in 2004, is privately held with offices in the US, United Kingdom, and Japan.
SyntheZyme develops bio-based products and technologies with a unique and competitive cost/performance. We work closely together with our industrial partners for the manufacture and marketing of our bio-based commodity and specialty products for the global market. We seek to complement our core competencies with those of our strategic, industrial partners. The success of our business is based on our capabilities to structure and operate entrepreneurial partnerships. SyntheZyme’s scientists and engineers have a deep knowledge in chemistry, synthetic biology, fermentation engineering and materials science with process know-how
NICO gives hope to patients with primary and secondary brain tumors, cysts and hemorrhagic strokes.